跳至主要内容
临床试验/CTRI/2019/04/018513
CTRI/2019/04/018513已完成未知

An open-label, balanced, randomized, single-dose, three-treatment, three-period, three-sequence, three-way crossover, oral relative bioavailability study of 2000mg of Curcuminoids from Liquid Curcumin of Halcyon Bioscience Pty Ltd, Sydney, Australia with 2000mg of Curcuminoids from reference product 1 (R1) - Curcuminoid Powder with Turmeric essential oil in vegetarian capsules and 2000mg of Curcuminoids from reference product 2 (R2) - Curcuminoid powder with Piperine in vegetarian capsules in normal, healthy, adult, human male subjects under fasting condition. - NA

Halycon Bioscience pty Ltd0 个研究点目标入组 9 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
9